DOCSLIB.ORG

Lot Lists of Pharmacopoeias EP, EPISA, ICRS, USP, BP January 2016

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lot Lists of Pharmacopoeias EP, EPISA, ICRS, USP, BP January 2016 Lot lists of Pharmacopoeias EP, EPISA, ICRS, USP, BP January 2016 New: LGCon Standards LinkedIn Pharma Dear user, LGC Standards created this pharmacopoeial lot list for you from actual data from the Pharmacopoeais and correct at the time of production. We retained all spelling and information as provided by the Pharmacopoeias. The list was compiled with caution, however errors in this list may be possible, and LGC Standards is not responsible for any consequences as a result of these errors, may it be errors in the original Pharmacopoeia data, or from LGC Standards during compilation of this list. For any questions or orders please contact your local LGC office. You will find all contact details on the last page of this list. Alternatively, you can browse and buy pharmaceutical refer- ence materials online at www.lgcstandards.com. Stay connected via LinkedIn (LGC Standards Pharma) or Twitter @LGCStdsPharma Kind regards Your LGC Standards Team LGC Standards, Queens Road, Teddington, Middlesex, TW11 0LY, United Kingdom Tel.: +44 (0)20 8943 8480, Fax: +44 (0)20 8943 7554 E-Mail: [email protected] Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPY0001756 Exemestane for system suitability 1 10 mg EPY0001561 Abacavir sulfate 1 20 mg EPY0001552 Abacavir for peak identification 1 10 mg EPY0001551 Abacavir for system suitability 1 10 mg EPY0000055 Acamprosate calcium - reference spectrum 1 n/a EPY0000116 Acamprosate impurity A 1 50 mg EPY0000500 Acarbose 3 100 mg EPY0000354 Acarbose for identification 1 10 mg EPY0000427 Acarbose for peak identification 3 20 mg EPA0040000 Acebutolol hydrochloride 1 50 mg EPY0000359 Acebutolol impurity B 2 10 mg EPY0000127 Acebutolol impurity C 1 20 mg EPY0000128 Acebutolol impurity I 2 0.004 mg EPY0000056 Aceclofenac - reference spectrum 1 n/a EPY0000085 Aceclofenac impurity F 2 15 mg EPY0000086 Aceclofenac impurity H 1 10 mg EPY0001094 Aceclofenac for peak identification 1 10 mg EPY0000810 Acemetacin 1 100 mg EPY0000811 Acemetacin impurity A 1 10 mg EPY0000842 Acemetacin impurity mixture 1 0.06 mg EPA0070000 Acesulfame potassium 2 50 mg EPA0070020 Acesulfame potassium impurity B 4 15 mg EPA0100000 Acetazolamide 1 100 mg EPY0001084 Acetazolamide for system suitability 2 0.0068 mg EPY0000002 Acetylcholine chloride 1 50 mg EPA0150000 Acetylcysteine 3 50 mg EPA0152000 Acetylcysteine impurity C 9 10 mg EPA0153000 Acetylcysteine impurity D 6 10 mg EPY0000565 ß-Acetyldigoxin 2 50 mg EPY0000642 ß-Acetyldigoxin for peak identification 1 10 mg EPA0200000 Acetylsalicylic acid 4 15 mg January 2016 New: LGC Standards Pharma on LinkedIn Pharmaceutical Lot List - NL Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPY0001460 Acetylsalicylic acid for peak identification 2 10.3 mg EPY0001462 Acetylsulfadiazine 1 0.002 mg EPA0208000 N-Acetyltryptophan 2 125 mg EPA0202000 N-Acetyltyrosine 1 200 mg EPY0000693 Acholeplasma laidlawii BRP 1 1 ml EPA0220000 Aciclovir 3 75 mg EPY0001271 Aciclovir for peak identification 1 3 0.303 mg EPY0001269 Aciclovir for peak identification 2 3 0.004 mg EPY0001264 Aciclovir for system suitability 1 10 mg EPA0225000 Acitretin 2 100 mg EPY0001463 Actaea racemosa HRS 1 1200 mg EPY0001543 Actaea racemosa for assay CRS 1 300 mg EPY0001464 Actaea racemosa dry extract for system suitability HRS 1 1200 mg EPY0001121 Adapalene 1 100 mg EPY0001120 Adapalene impurity C 3 6 mg EPY0001119 Adapalene for peak identification 2 2.022 mg EPA0230000 Adenine 2 50 mg EPA0230200 Adenosine 1 50 mg EPY0000110 Adipic acid 1 50 mg EPY0000882 Adrenaline 1 5 mg EPY0000740 Adrenaline impurity mixture 3 0.0045 mg EPY0000883 Adrenaline with impurity F 1 10 mg EPA0300000 Adrenaline tartrate 5 100 mg EPY0000707 Adrenaline tartrate with impurity A 1 15 mg EPY0001724 Agnus castus fruit dry extract 1 350 mg EPA0325000 Alanine 3 60 mg EPA0325100 Albendazole 2 50 mg EPA0325200 Alcuronium chloride 2 50 mg EPA0325450 Alfacalcidol 9 5 mg EPY0001601 Alfacalcidol for system suitability 1 2.5 mg EPA0325451 Alfacalcidol - reference spectrum 1 n/a January 2016 New: LGC Standards Pharma on LinkedIn Pharmaceutical Lot List - NL Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPA1225000 Alfadex 3 150 mg EPA0325500 Alfentanil hydrochloride - reference spectrum 1 n/a EPA0325800 Alfuzosin hydrochloride 2 10 mg EPY0000832 Alfuzosin for system suitability 1 10 mg EPY0001583 Alimemazine hemitartrate 1 15 mg EPY0001581 Alimemazine for system suitability 1 5 mg EPA0349000 Allantoin 1 60 mg EPA0350000 Allopurinol 3 100 mg EPA0350010 Allopurinol impurity A 2 10 mg EPA0350020 Allopurinol impurity B 3 10 mg EPA0350030 Allopurinol impurity C 3 10 mg EPA0350040 Allopurinol impurity D 4 15 mg EPA0350050 Allopurinol impurity E 1 20 mg EPA0351000 Allylstrychnine bromide 1 10 mg EPY0000235 Almagate 1 25 mg EPY0000255 Almagate - reference spectrum 1 n/a EPA0357000 Alprazolam - * psy 2 100 mg EPA0360000 Alprenolol hydrochloride 1 100 mg EPY0000054 Alprostadil 2 50 mg EPY0000606 Altizide 2 150 mg EPY0000843 Altizide impurity B 1 15 mg EPY0000687 Alverine citrate 1 5 mg EPY0000607 Alverine impurity D 1 10 mg EPY0000595 Alverine for peak identification 2 0.125 mg EPA0363000 Amantadine hydrochloride 1 100 mg EPA0363700 Ambroxol hydrochloride 3 125 mg EPA0900000 Amfetamine sulfate - reference spectrum 1 n/a EPA0365000 Amidotrizoic acid dihydrate 1 100 mg EPY0001461 Amidotrizoic acid for system suitability 1 0.08 mg EPA0368000 Amikacin 3 200 mg EPY0001467 Amikacin impurity I 1 20 mg January 2016 New: LGC Standards Pharma on LinkedIn Pharmaceutical Lot List - NL Available Current Unit Cat. No. Name What is new? since Batch No. Quantity 22/12/2015 EPY0001117 Amikacin for system suitability 3 10 mg New batch! EPA0365900 Amikacin sulfate 3 200 mg EPA0370000 Amiloride hydrochloride 2 100 mg EPY0000020 Amiloride impurity A 3 20 mg EPY0000173 4-Aminobenzoic acid 2 60 mg EPA0420000 Aminocaproic acid 1 50 mg EPA0460000 7-Aminodesacetoxycephalosporanic acid 2 20 mg EPA0496000 Aminoglutethimide 1 125 mg EPA0496005 Aminoglutethimide impurity A 1 20 mg EPA0496020 Aminoglutethimide impurity D 1 10 mg EPA0575000 Amiodarone hydrochloride 3 100 mg EPY0000129 Amiodarone impurity D 3 20 mg EPY0000130 Amiodarone impurity E 3 20 mg EPA0590000 Amisulpride 2 10 mg EPY0001534 Amisulpride for system suitability 1 1.0015 mg EPY0000563 Amitriptyline hydrochloride 1 10 mg EPY0000049 Amlodipine besilate 4 150 mg EPY0001068 Amlodipine impurity A 3 15 mg EPY0001069 Amlodipine impurity B 2 15 mg EPY0001070 Amlodipine impurity G 3 10 mg EPY0001067 Amlodipine for peak identification 2 15 mg EPY0000302 Ammonio methacrylate copolymer(type A) - reference spectrum 1 n/a EPY0000303 Ammonio methacrylate copolymer(type B) - reference spectrum 1 n/a EPA0650000 Amobarbital - * psy 1 500 mg EPA0700000 Amobarbital sodium - * psy 1 500 mg EPA0800000 Amoxicillin trihydrate 5 200 mg EPY0001521 Amoxicillin trihydrate for performance verification 1 5000 mg EPY0000005 Amphotericin B 5 100 mg EPY0001361 Amphotericin B for microbiological assay 1 100 mg EPY0001014 Amphotericin B for peak identification 2 10 mg EPA1000000 Ampicillin (anhydrous) 5 220 mg January 2016 New: LGC Standards Pharma on LinkedIn Pharmaceutical Lot List - NL Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPA1100000 Ampicillin trihydrate 2 150 mg EPY0001244 Amylmetacresol 1 285 mg EPY0001245 Amylmetacresol for peak identification 1 10 mg EPY0001522 Anastrozole 1 100 mg EPY0001531 Anastrozole impurity E 1 10 mg EPY0001753 Anemarrhena rhizome for system suitability HRS 1 150 mg EPY0001386 Angelica dahurica root HRS 1 160 mg EPY0001385 Angelica pubescens root 1 500 mg EPA1200000 Anhydrotetracycline hydrochloride 4 15 mg EPY0001466 Anhydrous Docetaxel 1 15 mg EPA1210000 Antazoline hydrochloride 1 50 mg 22/12/2015 EPY0001777 Apigenin 7-glucoside 1 25 mg New compound! EPY0001465 Apomorphine hydrochloride hemihydrate 1 15 mg EPY0001471 Apomorphine impurity B (morphine sulfate) * - narc 1 40 mg EPA1220000 Alpha-apo-oxytetracycline 5 20 mg EPA1230000 Beta-apo-oxytetracycline 5 20 mg EPY0001154 Aprotinin for system suitability 1 2.7 mg EPA1250000 Aprotinin solution BRP 4 0.5 mL EPA1269000 L-Arabinitol 2 10 mg EPY0000806 Arbutin 1 100 mg EPA1270000 Arginine 4 60 mg EPY0000304 Arginine aspartate 1 20 mg EPA1271000 Arginine hydrochloride 3 60 mg EPY0001649 Aripiprazole 1 170 mg EPY0001650 Aripiprazole impurity F 2 15 mg EPY0001323 Aristolochia n/a 140 mg EPY0001185 Aristolochic acid I 1 11 mg EPY0001175 Aristolochic acid for system suitability 1 1 mg EPY0000079 Articaine hydrochloride 3 200 mg EPY0000080 Articaine impurity A 3 25 mg EPY0000081 Articaine impurity E 2 10 mg January 2016 New: LGC Standards Pharma on LinkedIn Pharmaceutical Lot List - NL Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPY0001091 Artichoke leaf dry extract HRS 1 60 mg EPA1300000 Ascorbic acid 4 100 mg EPY0001024 Ascorbic acid impurity C 3 20 mg EPY0001170 Ascorbic acid impurity D 2 10 mg EPY0000800 Ascorbyl palmitate 1 10 mg EPY0001206 Asiaticoside 1 40 mg EPY0000305 Asparagine monohydrate 1 60 mg EPA1320000 Aspartame 2 40 mg EPA1321000 Aspartame impurity A 4 10 mg EPA1330000 Aspartic acid 2 50 mg EPY0001171 Astragaloside IV 1 40 mg EPA1340000 Atenolol 3 100 mg EPY0001089 Atenolol for system suitability 1 5 mg EPY0001586 Atomoxetine hydrochloride 1 110 mg EPY0001588 Atomoxetine impurity B 1 10 mg EPY0001589 Atomoxetine impurity D 1 5 mg EPY0001587 Atomoxetine for impurity A identification 1 10 mg EPY0001327 Atorvastatin calcium trihydrate 2 150 mg EPY0001328 Atorvastatin impurity A 2 10 mg EPY0001329 Atorvastatin impurity B 2 10 mg EPY0001330 Atorvastatin impurity C 2 10 mg EPY0001331 Atorvastatin impurity D 2 10 mg EPY0001332 Atorvastatin impurity E 2 10 mg EPY0001572 Atovaquone 1 270 mg EPY0001573 Atovaquone for system suitability 1 10 mg EPY0000424 Atracurium besilate 2 120 mg EPY0000503 Atracurium for impurity F identification 1 5 mg EPY0000504 Atracurium for peak identification 1 5 mg EPY0000878 Atropine 1 30 mg EPY0000816 Atropine impurity B 1 10 mg EPY0000845 Atropine for peak identification 2 0.25 mg January 2016 New: LGC Standards Pharma on LinkedIn Pharmaceutical Lot List - NL Available Current Unit Cat.
Load more

Recommended publications
  • THIORIDAZINE Thioridazinum
    EUROPEAN PHARMACOPOEIA 5.8 Thioridazine Detection: spectrophotometer at 240 nm. C. R = CO-C2H5 : testosterone propionate, Injection: 20 µl of the test solution and reference β D. R = CO-CH(CH3)2 : 3-oxoandrost-4-en-17 -yl solutions (a) and (b). 2-methylpropanoate (testosterone isobutyrate), Run time: twice the retention time of testosterone β isocaproate. E. R = CO-[CH2]4-CH3 : 3-oxoandrost-4-en-17 -yl hexanoate (testosterone caproate), Identification of impurities: use the chromatogram supplied with testosterone isocaproate for system suitability CRS F. R = CO-[CH2]5-CH3 : testosterone enantate, and the chromatogram obtained with reference solution (a) toidentifythepeaksduetoimpuritiesA,B,C,D,E,FandG. Relative retention with reference to testosterone isocaproate (retention time = about 14 min): impurity A = about 0.2; impurity B = about 0.4; impurity C = about 0.5; impurity D = about 0.7; impurity G = about 0.8; impurity E = about 1.1; impurity F = about 1.4. System suitability: reference solution (a): G. 3-oxoandrost-4-en-17α-yl 4-methylpentanoate — peak-to-valley ratio: minimum 2.5, where Hp =height abovethebaselineofthepeakduetoimpurityEand (epitestosterone isocaproate). Hv = height above the baseline of the lowest point of the curve separating this peak from the peak due to testosterone isocaproate. 07/2007:2005 Limits: — impurities A, B, C, D, E, F, G:foreachimpurity,notmore THIORIDAZINE than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent); Thioridazinum — unspecified impurities: for each impurity, not more than 0.2 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.10 per cent); — total: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (1.0 per cent); — disregard limit: 0.1 times the area of the principal peak in the chromatogram obtained with reference solution (b) C H N S M 370.6 (0.05 per cent).
    [Show full text]
  • Pharmaceutical Sciences
    IAJPS 2017, 4 (08), 2671 - 2680 V.L.Sravani et al ISSN 2349 - 7750 CODEN [USA]: IAJPBB ISSN: 2349 - 7750 I N D O A M E R I C A N J O U R N A L O F P H A R M A C E U T I C A L S C I E N C E S Available online at: http://www.iajps.com Research Article ANTI - ACNE ACTIVITY OF LIPIDO - STEROLIC EXTRACT OF SERENOA REPENS AND HYDRO - ALCOHOLIC EXTRACT OF GLYCYRRHIZA GLABRA IN SYRIAN HAMSTER EAR MODEL V. Laxmi Sravani 1 *, Dr. B. Ch a n drasekhar Rao 1 , Dr. D. Ravi Krishna Babu 2 1 Department of Pharma cology, RGR Siddhanthi College of Pharmacy , Secundera bad. 2 Aurigene Discovery Technologies Pvt Ltd. Miyapur, Hyderabad. Abstract : Acne vulgaris is the most commonly encountered dermatological disease of pilosebaceous unit. Androgens, which increase during puberty, stimulate the sebaceous gland to produce sebum and cause retention of keratinocytes around the sebaceous hair follicle orifice causing partial to complete blockage and leading to colonization with Propionibacterium acnes, which participates in the production of pro inflammatory mediators. For treatment of acne one of the approaches is to reduce sebum production, the main stimulus to acne; then all other pathogenic factors will diminish. A comprehensive approach combining the natural medicine with anti - androgenic activity would be fruitful area for anti - acne therapy. In this context the well documented anti - androgenic herbs like liquorice and saw palmetto were selected and screened in Syrian hamster ear model using spironolactone as standard.
    [Show full text]
  • Kinetic-Performance and Selectivity Optimization in Supercritical Fluid Chromatography Sander Delahaye
    Kinetic-Performance and Selectivity Optimization in Supercritical Fluid Chromatography Thesis Submitted to the Faculty of Science in Fulfilment of the Requirements for the Degree of Doctor in Science (Chemistry) Sander Delahaye Promotor Prof. Dr. Frédéric Lynen Leden van de lees- en examencommissie: Voorzitter: Prof. Dr. J. Martins Vakgroep Organische en Macromoleculaire Chemie, Faculteit Wetenschappen, UGent Leescommissie: Prof. Dr. K. Broeckhoven Vakgroep Chemische Ingenieurstechnieken en Industriële Scheikunde (CHIS), Faculteit Ingenieurswetenschappen, Vrije Universiteit Brussel Prof. Dr. D. Cabooter Laboratorium Farmaceutische Analyse, Faculteit Farmaceutische Wetenschappen, KU Leuven Dr. L. Balcaen Vakgroep Analytische Chemie, Faculteit Wetenschappen, UGent Examencommissie: Dr. I. Francois UPC²/SFC & Strategic Separation Technologies Business Development Manager Europe and India (Waters) Prof. Dr. K. Van Geem Vakgroep Chemische Proceskunde en Technische Chemie Faculteit Ingenieurswetenschappen en Architectuur, UGent Prof. Dr. F. Lynen Vakgroep Organische en Macromoleculaire Chemie, Faculteit Wetenschappen, UGent This research was funded by the Agency for Innovation by Science and Technology in Flanders (IWT - Vlaanderen) Table of Contents I General Introduction and Scope 1 1. General introduction . .1 2. Scope . .5 3. References . .6 II The Emergence of Packed-Column Supercritical Fluid Chromatography as an Alternative for HPLC 9 1. Introduction . 10 2. Definition of supercritical fluids . 10 3. Physico-chemical properties of supercritical fluids . 10 4. The use of supercritical fluids as extraction solvent and as mobile phase in chromatography . 15 5. SFC over the years . 16 6. Contemporary pSFC conditions and stationary phases . 17 7. Most important applications of supercritical fluid chromatography . 20 7.1. Preparative SFC applications . 20 7.2. Analytical SFC applications . 21 8. Nomenclature issues . 21 9.
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • THE BARRON REPORT Volume 7, Issue 6 © 1999, Jon Barron
    THE BARRON REPORT Volume 7, Issue 6 © 1999, Jon Barron. All Rights Reserved. Health For Every Man Over 30 The Prostate Problem Like women, men too are exposed to the effects of chemical estrogens in their environment. In addition, as their testosterone levels drop with age, there is, in many cases, a concomitant rise in estradiol levels -- the major reason that many older men develop breasts. Just as with women, estradiol stimulates cell growth in men too and is potentially cancerous. Estradiol stimulates the BCL2 gene, which is the gene responsible for stopping cell death. What at first glance sounds like a positive, is, upon closer inspection, not. When cell death in prostate tissue, for example, is blocked, cell growth continues unabated -- becoming a major contributing factor in the enlargement of the prostate and the development of prostate cancer. This is one of the main factors involved in the dramatically increased incidence of prostate cancer. • A new case of Prostate Cancer is diagnosed every 3 minutes in America and every 15 minutes a man dies from prostate cancer. • Prostate Cancer is the second leading type of cancer among men. • 11 million men have some form of Prostate Cancer in the United States. • African-American men have the highest rate of Prostate Cancer in the world. • Survival rates for men with prostate cancer in 1995 were no different than they were in 1965. • The age at which Prostate Cancer develops will drop ten years by the year 2000. By the year 2000, Prostate Cancer will increase by 90%. The Prostate Solution Regular use of a men's progesterone crememakes a great deal of sense for any man over the age of 30.
    [Show full text]
  • The Metabolism of Anabolic Agents in the Racing Greyhound
    The Metabolism of Anabolic Agents In the Racing Greyhound A thesis submitted in partial fulfilment of the requirements for the Degree of Doctor of Philosophy by Mr. Keith Robert Williams, B.Sc. July 1999 Department of Forensic Medicine & Science University of Glasgow Copyright © 1999 by Keith R. Williams. All rights reserved. No part o f this thesis may be reproduced in any forms or by any means without the written permission o f the author. I ProQuest Number: 13833925 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 13833925 Published by ProQuest LLC(2019). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 GLASGOW UNIVERSITY LIBRARY 111-X (coK To my parents for all their help, support and encouragement i Table of Contents i List of Figures V List of Tables VIII Summary IX Chapter 1: Drugs in Sport ...............................................................................................................................1 Introduction .................................................................................................................................................
    [Show full text]
  • Pharmacopoeial Reference Standards and Their Current Lot Numbers EP, EPISA, ICRS, BP July 2019
    Pharmacopoeial reference standards and their current lot numbers EP, EPISA, ICRS, BP July 2019 Mikromol Follow LGC on LinkedIn Dear user, This catalogue includes all pharmacopoeial reference materials from EP, EPISA, ICRS and BP available at LGC, as well as their current lot numbers. We update the catalogue on a monthly basis so that you can use the lot numbers to easily track the expiry dates of your stocked reference materials. We took the lot information from actual data from pharmacopoeias, correct at the time of production. We retained all spelling and information as provided by the pharmacopoeias. The list was compiled with caution, however, errors in this list may be possible, and LGC is not responsible for any consequences as a result of these errors, may it be errors in the original Pharmacopoeial data, or from LGC during compilation of this list. For any questions or orders please contact your local LGC office. You will find all contact details on the last page of this list. Alternatively, you can browse and buy pharmaceutical reference materials online at lgcstandards.com/mikromol. Stay connected via LinkedIn (LGC Mikromol) or Twitter @LGCMikromol. Kind regards Your LGC Standards Team LGC, Queens Road, Teddington, Middlesex, TW11 0LY, United Kingdom Tel: +44 (0)20 8943 8480 Fax: +44 (0)20 8943 7554 E-mail: [email protected] European Pharmacopoeia (EP) Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPY0001552 Abacavir for peak identification 1 10 mg EPY0001551 Abacavir for system suitability 1
    [Show full text]
  • LEGISLATIVE ASSEMBLY Question on Notice
    LEGISLATIVE ASSEMBLY Question On Notice Thursday, 15 February 2018 2560. Ms M. M Quirk to the Minister for Police; I refer to the commencement of operation of the Road Traffic Amendment Act 2016 in March 2017 which introduced compulsory blood or urine samples to be taken from drivers involved in serious crashes, and I ask: (a) since March 2017 how many such samples have been taken; (b) for what specific substances are those blood or urine samples tested; (c) what are the results of those tests to date; and (d) what percentage of drivers have been found to have ingested more than one substance capable of impairing driving skills? Answer (a) The compulsory taking of blood from all drivers involved in serious crashes commenced on 10 March 2017. Between 10 March 2017 and 22 February 2018 (inclusive) a total of 398 blood test samples have been collected under the provision of the Road Traffic Amendment Act 2016. There have been no urine tests collected. (b) Please see attached table for a list of substances in blood sample that are identifiable in ChemCentre toxicology analysis (Paper Number). (c) Of the 398 blood samples collected, 48 are pending results of ChemCentre analysis. Of the 350 analysed, 259 samples had a specific substance(s) detected and 91 samples had no specific substance detected. d) Of the 259 samples with specific substance(s) detected, 92% were found to have multiple substances (more than one). Detectable Substances in Blood Samples capable of identification by the ChemCentre WA. ACETALDEHYDE AMITRIPTYLINE/NORTRIPTYLINE
    [Show full text]
  • LAURABOLIN® 25 Mg/Ml LAURABOLIN® 50 Mg/Ml
    502/0033/883/090430F 20-09-2004 16:38 Pagina 1 090430F 0033.883.2100 PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY ® Showing – one injection 3-4 weeks before. If used in performance animals, the regulations of the relevant authorities regarding LAURABOLIN 25 mg/mL medication should be observed. ANABOLIC STEROID FOR INTRAMUSCULAR OR SUBCUTANEOUS INJECTION DIRECTIONS FOR USE: ® RESTRAINT: DO NOT USE in food producing species of animal. LAURABOLIN 50 mg/mL PRECAUTIONS: ANABOLIC STEROID FOR INTRAMUSCULAR OR SUBCUTANEOUS INJECTION Androgens can induce masculinisation of a female foetus and may have a suppressive effect on sexual development in young male animals. ACTIVE CONSTITUENT: NANDROLONE LAURATE DOSAGE AND ADMINISTRATION: Use the contents of the vial within 24 hours of initial broaching. Discard any unused portion. For long term anabolic therapy in Horses, Dogs and Cats. Give once each month by subcutaneous or intramuscular injection. MODE OF ACTION: Dose rate is 1 mg/kg bodyweight. LAURABOLIN® contains the highly active anabolic steroid 19 –norandrostenolone Dogs up to 50 mg monthly. (Nandrolone) laurate in oil solution. Cats up to 25 mg monthly. ® Horses up to 200 mg monthly. NANDROLIN (Nandrolone Phenylpropionate B.P.) was the first anabolic agent to be Foals up to 100 mg monthly. made available with negligible androgenic activity for veterinary use and has gained wide acceptance in clinical practice. LAURABOLIN® (Nandrolone laurate) is an advanced In chronic conditions or prolonged convalescence, injections should be made at three development, aimed at providing for those conditions where fewer injections at longer week intervals. In mares allow 6 weeks from injection date to mating date.
    [Show full text]
  • The 5ARI Withdrawal Syndrome (5ARI-WS)
    The 5ARI Withdrawal Syndrome (5ARI-WS) The Silenced Androgen Receptor (AR) Theory: Explaining persistent side effects arising from 5alpha reductase (5AR) inhibitor (5ARI) use By “Awor” and “Mew”, Administrators of Propeciahelp.com (July 2010) 1. Introduction An increasingly overwhelming amount of evidence is starting to accumulate from various doctors, scientists, patient groups and online discussion forums, whereby seemingly unrelated substances such as finasteride, dutasteride, isotretinoin and saw palmetto extract (SPE) based preparations are causing young consumers to suffer from long-term, irreversible and serious health damage. The experienced persistent side effect have a clear denominator in that they all seem to relate to physiological and psychological functions which require androgens to function correctly: Loss of libido (1) (2) Low energy, fatigue (1) Depression (including suicidal depression)* (3) (4) (5) (6) Impaired thought processes* (7) Memory failure* (7) Erectile dysfunction (8) (9) (2) Penile atrophy (9) Impaired spermatogenesis (10) (11) (12) Muscle wasting (13) (14) (15) Gynecomastia (16) Dry skin and dry eyes (17) (18) (19) Prostate problems (2) Metabolic syndrome (20) Osteoporosis (21) (22) Anxiety and sleep disorders, muscle spasms (23) (24) (25) * Indirect action through 3α-HSD as described later in this document Of substantial note is that most side effects typically surface or reach full extent roughly 10-14 days after quitting the 5ARI substances. Androgen dependent tissue atrophy (penile, scrotum,
    [Show full text]
  • Drugs and Related Substances
    CHAPTER 63:04 - DRUGS AND RELATED SUBSTANCES: SUBSIDIARY LEGISLATION (previously "HABIT-FORMING DRUGS") INDEX TO SUBSIDIARY LEGISLATION Declaration of Habit-Forming Drugs Order Drugs and Related Substances Regulations Habit-Forming Drugs (Exempted Preparations) Regulations Habit-Forming Drugs Regulations HABIT-FORMING DRUGS REGULATIONS (under section 12 ) (3rd October, 1922 ) ARRANGEMENT OF REGULATIONS REGULATION 1. Citation 2. Export of habit-forming drugs 3. Form of permit First Schedule - Permit to Export Opium or other Habit-Forming Drugs Second Schedule - Permit to Import or Acquire Habit-Forming Drugs HCN 68, 1922, HCN 87, 1922, HCN 195, 1937, HMC Order 1, 1963, L.N. 84, 1966, S.I. 12, 1977. 1. Citation These Regulations may be cited as the Habit-forming Drugs Regulations. 2. Export of habit-forming drugs Any duly registered medical practitioner, dentist or chemist and druggist, and any duly qualified veterinary surgeon who is desirous of exporting from Botswana any habit-forming drug as defined in the Act (other than prepared opium as defined in the Act), shall- (a) furnish to the Minister a certificate from the government or administration of the importing country to the effect that such government or administration is satisfied that the consignment of such habit-forming drug is required solely for medicinal or scientific purposes, and that it approves of its importation; (b) obtain from the Minister a permit under section 4(4) of the Act in the form in the First Schedule hereto. 3. Form of permit The form of permit to import or acquire habit-forming drugs as provided for in section 5(1) of the Act shall be as contained in the Second Schedule hereto.
    [Show full text]
  • Beta-Sitosterol [BSS] and Betasitosterol Glucoside [BSSG] As an Adjuvant in the Treatment of Pulmonary Tuberculosis Patients.” TB Weekly (4 Mar 1996)
    Saw Palmetto (Serenoa repens) and One of Its Constituent Sterols -Sitosterol [83-46-5] Review of Toxicological Literature Prepared for Errol Zeiger, Ph.D. National Institute of Environmental Health Sciences P.O. Box 12233 Research Triangle Park, North Carolina 27709 Contract No. N01-ES-65402 Submitted by Raymond Tice, Ph.D. Integrated Laboratory Systems P.O. Box 13501 Research Triangle Park, North Carolina 27709 November 1997 EXECUTIVE SUMMARY The nomination of saw palmetto and -sitosterol for testing is based on the potential for human exposure and the limited amount of toxicity and carcinogenicity data. Saw palmetto (Serenoa repens), a member of the palm family Arecaceae, is native to the West Indies and the Atlantic Coast of North America, from South Carolina to Florida. The plant may grow to a height of 20 feet (6.10 m), with leaves up to 3 feet (0.914 m) across. The berries are fleshy, about 0.75 inch (1.9 cm) in diameter, and blue-black in color. Saw palmetto berries contain sterols and lipids, including relatively high concentrations of free and bound sitosterols. The following chemicals have been identified in the berries: anthranilic acid, capric acid, caproic acid, caprylic acid, - carotene, ferulic acid, mannitol, -sitosterol, -sitosterol-D-glucoside, linoleic acid, myristic acid, oleic acid, palmitic acid, 1-monolaurin and 1-monomyristin. A number of other common plants (e.g., basil, corn, soybean) also contain -sitosterol. Saw palmetto extract has become the sixth best-selling herbal dietary supplement in the United States. In Europe, several pharmaceutical companies sell saw palmetto-based over-the-counter (OTC) drugs for treating benign prostatic hyperplasia (BPH).
    [Show full text]